Acusphere, a pharmaceutical firm, has announced that there has been no U.S. FDA statement on its experimental cardiovascular drug, Imagify. The Watertown, Mass.-based believes that Imagify with ultrasound will provide an alternative to nuclear stress testing in diagnosing artery disease.

In May, Acusphere said its second Phase 3 clinical trial of Imagify injectable suspension did not achieve the specificity endpoint that the company had previously reported in its fist Phase 3 trial.

The firm plans to file its new drug application with the FDA in early next year, instead at this year’s end, as it previously intended.